Gilead Sciences (GILD) Tops Q4 EPS by 17c; Guides
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2023 Dividend
February 2, 2023 4:05 PM ESTFOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the companys Board of Directors has declared an increase of 2.7% in the companys quarterly cash dividend, beginning in the first quarter of 2023. The increase will result in a... More
Gilead Sciences Announces Fourth Quarter and Full Year 2022 Financial Results
February 2, 2023 4:01 PM ESTProduct Sales Excluding Veklury Increased Year-Over-Year by 8% for Full Year 2022
Biktarvy Sales Increased Year-Over-Year by 20% for Full Year 2022
Oncology Sales Increased Year-Over-Year by 71% for Full Year 2022
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2022.
2022 marked Gileads strongest full year growth in our base business since HCV sales peaked in 2015. This return to growth was driven by consistent and high quality... More
